



I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, is being deposited with the Postal Service with sufficient postage to be sent as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on: 3/28/01

By: Winsome A. Dunn

Winsome A. Dunn

RECEIVED

APR 13 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Ning Zhang, et al.

SERIAL NO.: 09/465,978

FILED: December 16, 1999

FOR: **Methods and Compositions for Screening  
for Angiogenesis Modulating Compounds**

EXAMINER: R. Shukla

ART UNIT: 1632

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES AND PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231  
Box: Sequence

Sir:

In response to the Office action mailed February 28, 2001, in the above-identified application, please amend the application as follows.

**IN THE SPECIFICATION:**

Please replace the originally-filed Sequence Listing with the enclosed substitute pages containing the Sequence Listing.

**REMARKS**

In the Office Action dated, February 28, 2001, The Examiner has noted that the subject application fails to comply with the requirements of 37 CFR 1.821-1.825, for failing to include the Sequence Listing in computer-readable form (CRF). The Examiner has requested (i) an initial or substitute CRF copy of the Sequence Listing, (ii) an initial or substitute paper copy of the Sequence Listing together with an amendment directing its entry into the specification, and (iii) a statement that the content of the paper and computer readable copies are the same, and that they do not introduce new matter.